Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: REFRESH PLUS® Clear all
Active, not recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

NCT02280473
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive® Gel Drops, REFRESH LIQUIGEL®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Petaluma, California • San Diego, California • Bangor, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

NCT00544713
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Sep 9, 2026, 8:24 AM EDT
Terminated Not applicable Interventional Results available

CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery

NCT03384875
View directory record Official record
Conditions
Elective Cardiac Surgery
Interventions
CytoSorb
Device
Lead sponsor
CytoSorbents, Inc
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

NCT04393441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Azusa, California • Glendale, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 9, 2026, 8:24 AM EDT
Recruiting Phase 4 Interventional

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

NCT07676084
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial tears
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare a New Eye Drop Formulation With Refresh Contacts®

NCT01844388
View directory record Official record
Conditions
Contact Lens Lubrication
Interventions
carboxymethylcellulose based eye drop formula, carboxymethylcellulose sodium based eye drop solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Bloomington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT06544694
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial Tears
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01072357
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear

NCT00691197
View directory record Official record
Conditions
Ametropia
Interventions
Carboxymethylcellulose sodium and Glycerin, Carboxymethylcellulose sodium
Device
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 9, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

NCT01459588
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Eye Drop Formulation B, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops, Carboxymethylcellulose Based Lubricant Eye Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 9, 2026, 8:24 AM EDT